01
Source material
Autologous blood, fat, tissue, cells and non-autologous products are separated.
Regenerative Approaches · Product and Tissue Identity · Istanbul
Regenerative Approaches
PRP, PRF, adipose- or tissue-derived preparations, cell-based approaches, extracellular-vesicle claims and PN/PDRN are not one product class. Source, processing, cellular content, manufacture, authorisation and evidence must remain separate.
The word regenerative does not prove tissue renewal, clinical benefit or durability. Every method below links once to its existing English canonical page.
Physician-Led Orientation
Four levels before method selection
A reasoned sequence begins with the clinical question.
Online review can organise the question. Final suitability follows from in-person examination, the exact product or device and an individual risk–benefit assessment.
02
Processing and content
Cell presence or absence, viability, matrix, soluble factors and manufacturing are made explicit.
03
Licence and evidence
Product, indication, route and regional authorisation are checked together.
04
Clinical boundary
Risks, alternatives, follow-up and a no-treatment option remain visible.
Regenerative Approaches · 01–03
Blood and tissue preparations
Autologous source does not make preparations equivalent.
PRP, PRF and micrografts differ in starting material, processing, cellular content and evidence.
01Existing EN-I4/EN-I5 route
PRP
Autologous plasma fraction; protocol-dependent platelet and cellular composition.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open PRP02Existing EN-I4/EN-I5 route
PRF and Autologous Platelet Concentrates
Blood-derived preparations with distinct anticoagulant, clot and processing choices.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open PRF and Autologous Platelet Concentrates03Existing EN-I4/EN-I5 route
Autologous Microtransplantation
Tissue-derived micrograft preparation; cell and matrix content depend on processing.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Autologous MicrotransplantationRegenerative Approaches · 04–06
Adipose tissue and extracellular-vesicle claims
Tissue structure, cells and manufactured products require separate descriptions.
SVF, microfat/nanofat and exosome-based approaches retain different legal and evidentiary questions.
01Existing EN-I4/EN-I5 route
Stromal Vascular Fraction (SVF)
Adipose-tissue-derived heterogeneous preparation with processing and regulatory boundaries.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Stromal Vascular Fraction (SVF)02Existing EN-I4/EN-I5 route
Microfat and Nanofat
Fat- and tissue-derived preparations with different particle, cellular and structural properties.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Microfat and Nanofat03Existing EN-I4/EN-I5 route
Exosome-Based Approaches
Product-source, extracellular-vesicle characterisation, manufacturing and authorisation claims require verification.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Exosome-Based ApproachesRegenerative Approaches · 07–08
Nucleic-acid-derived and cell-based approaches
PN/PDRN and stem-cell approaches are not one biological category.
Source, cell status, manufacture, route, authorisation and evidence remain explicit.
01Existing EN-I4/EN-I5 route
Polynucleotides, PN and PDRN
Different nucleic-acid-derived products; source, formulation, licence and evidence are product-specific.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Polynucleotides, PN and PDRN02Existing EN-I4/EN-I5 route
Stem-Cell-Based Approaches
Cell identity, manipulation, viability, manufacture, indication and regulation must be explicit.
Decision boundaryLinked to one existing canonical; no regenerative outcome is guaranteed.
Open Stem-Cell-Based ApproachesQuality and Safety Framework
Four binding principles
Premium care means clearer selection, boundaries and follow-up.
Advertising language and package logic are replaced by product traceability, anatomy, proportionate alternatives and documented review.
01
Source before slogan
The starting material is named without implying regeneration.
02
Process before equivalence
Preparation and cellular content determine what the product is.
03
Licence before promise
Authorisation is checked by product, route, indication and region.
04
Evidence before repetition
Clinical endpoints and stopping criteria precede another intervention.
Bağdat Caddesi · Istanbul
International patient pathway
Travel, examination and follow-up form one medical process.
The in-person appointment remains the decision point. Product records, early safety, return travel and local medical access are considered before treatment.
- 01Before travel
Organise the question
History and records prepare discussion without confirming a biological product.
- 02In Istanbul
Examine and verify
Diagnosis, source, preparation, product status, risks and alternatives are reviewed.
- 03Treatment day
Keep traceability
Source, processing, batch where relevant, route and observations remain recorded.
- 04After return
Review without attribution
Safety and agreed endpoints are assessed without assuming every change is regenerative.
The Doctor Aslan Approach
Biological identity before regenerative language
Different preparations keep different medical boundaries.
Doctor Aslan separates source, processing, cellular content, manufacture, authorisation and evidence before considering any clinical role.
Name the source
Blood, fat, tissue, cells and manufactured materials remain distinct.
Audit preparation
Processing and cell presence or absence stay traceable.
Limit the claim
No tissue renewal, collagen response, permanence or personal benefit is guaranteed.
Accept alternatives
Established care, observation or no intervention can take priority.
Medical responsibility: Dr İsmail AslanMedical review: 24 August 2026General patient information; no regeneration, product or outcome guarantee
Frequently Asked Questions
Short and clear
Questions commonly asked before a decision.
These answers provide general orientation and do not replace personal diagnosis or treatment planning.
01What is Regenerative Approaches?+
Regenerative Approaches is described on this page as one defined clinical route. Its role, limits and possible alternatives are considered together rather than treating the method name as a personal recommendation.
02Who may be assessed for Regenerative Approaches?+
Suitability depends on the medical question, history, examination, the exact product or device where relevant, realistic aims and an individual benefit–risk assessment.
03What remains undecided after an online review?+
Diagnosis, definitive suitability, the treatment protocol, product, dose or device settings, expected response and the option not to proceed remain subject to personal medical assessment.
04How are treatment and follow-up in Istanbul planned?+
The in-person examination remains the decision point. Expected early reactions, warning signs, the direct contact route, return travel and access to appropriate local medical care are discussed before treatment.
Next Step
Name the source · define the product · examine the evidence